Navigation Links
Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
Date:7/14/2009

LAGUNA NIGUEL, Calif., July 14 /PRNewswire/ -- Inspiration Biopharmaceuticals today announced the presentation of positive preclinical safety, toxicology and preliminary pharmacokinetic data on its lead product, IB1001, a novel recombinant Factor IX product to treat patients with hemophilia B. The data were highlighted in an oral presentation yesterday at the XXII Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Boston, Mass. IB1001 has completed preclinical testing and is currently being evaluated in a Phase 1/2-3 clinical study.

In the study, the safety, toxicology and pharmacokinetics of IB1001 were evaluated in animal models and compared to commercially available Factor IX products. Results showed that IB1001 has an excellent safety profile in animal models and a similar pharmacokinetic profile when compared to currently available Factor IX products.

"These results and the progress that we have made in advancing our protein manufacturing technology have facilitated the advancement of IB1001 into a Phase 1/2-3 clinical program," said Michael Griffith, Ph.D., President and CEO, Inspiration Biopharmaceuticals. "Our ultimate goal is to increase accessibility to prophylactic treatment and improve the quality of life for people suffering from hemophilia around the world. We expect to move IB1001 into a pivotal trial and look forward to updating you on all developments related to this program."

About IB1001

IB1001 is an intravenous recombinant Factor IX product for the acute and preventative treatment of the bleeding disorder associated with hemophilia B. IB1001 is produced with Inspiration's proprietary recombinant protein manufacturing technology, which significantly increases cell-line productivity.

About Hemophilia

Hemophilia is a lifelong, inherited bleeding disorder cause
'/>"/>

SOURCE Inspiration Biopharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals
2. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
3. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
4. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
6. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
7. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
8. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
9. The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
(Date:1/14/2014)... Jan. 14, 2014  3D Communications, a leading provider of strategic communications ... and media events in the United States ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... June 11 The Champalimaud Foundation, one of ... J. Anthony Movshon , Director of New York ... T. Newsome , Investigator at The Howard Hughes Medical Institute ... the recipients of its 2010 Vision Award.  The prestigious Champalimaud ...
... June 5 Delcath Systems, Inc. (Nasdaq: ... device company focused on oncology, highlighted the Phase III ... the American Society of Clinical Oncology,s 2010 Annual Meeting, ... alternative care for patients with hepatic metastases from ocular or ...
... ... of the influenza virus and its human host, post-graduate student Stephen Huff of the University ... software downloads - best of all, the service is free. , ... (PRWEB) June 5, 2010 -- We call them computer ...
Cached Biology Technology:Prestigious International Champalimaud Vision Award to US Scientists 2Prestigious International Champalimaud Vision Award to US Scientists 3Prestigious International Champalimaud Vision Award to US Scientists 4Delcath Highlights Phase III Trial Results Presented at ASCO 2Delcath Highlights Phase III Trial Results Presented at ASCO 3Computational Microbiologist Uses His Expertise with Deadly Viruses to Devise a Superior System for Delivery of Safe, Free Software Downloads 2Computational Microbiologist Uses His Expertise with Deadly Viruses to Devise a Superior System for Delivery of Safe, Free Software Downloads 3Computational Microbiologist Uses His Expertise with Deadly Viruses to Devise a Superior System for Delivery of Safe, Free Software Downloads 4
(Date:4/16/2014)... director of the Physical Biosciences Division of Lawrence Berkeley ... recognized as a leading authority on the evolutionary design ... to systems and synthetic biology, has been named one ... Award by U.S. Energy Secretary Ernest Moniz. The E.O. ...
(Date:4/16/2014)... Geologic and soil processes are to blame for significant ... a study published recently in the Journal of Environmental ... all corners of Ohio showed that every single sample had ... the U.S. Environmental Protection Agency. The findings should not alarm ...
(Date:4/15/2014)... neurobiologists have found that genetically modified neural stem cells show ... the symptoms and pathology of Alzheimer,s disease. The pre-clinical trial ... Therapy , and the approach has been shown to work ... of the most common forms of dementia, is associated with ...
Breaking Biology News(10 mins):Berkeley Lab's Adam Arkin wins 2013 Lawrence Award 2Berkeley Lab's Adam Arkin wins 2013 Lawrence Award 3Significant baseline levels of arsenic found in Ohio soils are due to natural processes 2Significant baseline levels of arsenic found in Ohio soils are due to natural processes 3Significant baseline levels of arsenic found in Ohio soils are due to natural processes 4UCI study finds modified stem cells offer potential pathway to treat Alzheimer's disease 2
... London is part of an international consortium of scientists who ... euros, over ten years, to simulate ,everything we know about ... Science, Health and Medicine at King,s is a partner in ... dozens of groups of neuroscientists from many countries in Europe, ...
... service that is designed to make it quick and ... philanthropically-funded and not-for-profit, this project builds on the belief ... the coming era of Web-native science. , ImpactStory is ... data and radical transparency for the future of science. ...
... are caused by bacteria resistant to antibiotics and ... it is becoming increasingly difficult to treat infected patients ... which was published today, the Academy of Sciences and ... Sciences Leopoldina list eight recommendations that show ways to ...
Cached Biology News:Human Brain Project funded - 1 billion euros to map the human brain 2ImpactStory metrics of academic research outreach piloted by Pensoft Publishers 2
... been designed for recovery of DNA from TAE and ... Ultra fast protocol: DNA is ready to use ... to resuspend Bead uniformity prevents shearing of high ... PCR) DNA is eluted into sterile water or ...
... enables efficient extraction of DNA fragments from 150 bp ... The procedure uses GelMelt solution to dissolve the gel ... silica membrane in a spin column format. After a ... buffer. Each spin column can bind up to 20 ...
... of DNA from agarose gels The SpinPrep Gel ... 150 bp to > 12,000 bp in size from ... the gel slice, followed by adsorption of the DNA ... After a wash step, the purified DNA is eluted ...
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human HLA-DR TAC is designed to deplete human HLA-DR from samples to isolate resting CD4+ or CD8+ T cells....
Biology Products: